3. Animal study results
Preclinical studies using mouse models have provided the most substantial evidence for PCC1’s potential benefits. In one notable study, older mice treated intermittently with PCC1 showed improved physical performance metrics such as endurance and grip strength. Moreover, these mice exhibited an average lifespan extension of approximately 9%.
Remarkably, very old mice—those equivalent to advanced human age—experienced an increase in remaining lifespan by up to 60% in some cases. These results suggest a pronounced effect on late-life health and survival, although the mechanisms may differ at various stages of aging.
It is important to emphasize that while these findings are promising, animal models do not perfectly replicate human physiology. Therefore, these results provide a foundation but not conclusive proof of efficacy in humans.
4. Lonvi Biosciences’ developments
Lonvi Biosciences, a startup based in Shenzhen, China, has focused on translating PCC1 research into a practical supplement format. Their efforts have produced a concentrated PCC1 capsule designed to target senescent cells selectively, aiming to reduce chronic inflammation associated with aging.
Company statements describe ambitious goals, including the potential to significantly extend human healthspan and possibly lifespan. While the company has refined its product and moved toward commercial readiness, detailed information about formulation purity, dosing, and safety profiles has not been fully disclosed publicly.
5. Human clinical trial status
As of now, no completed human clinical trials have validated the lifespan-extending effects of PCC1 observed in mice. Lonvi Biosciences and other researchers are reportedly planning or initiating early-phase trials to assess safety, tolerability, and biomarkers of aging in humans.
Human studies face challenges such as longer timeframes, complex aging biology, and ethical considerations. Until rigorous, peer-reviewed clinical data are available, the longevity claims remain speculative. Experts advise cautious optimism, emphasizing that translating senolytic therapies from animals to humans requires extensive validation.
